Allogeneic SCT May Be Effective for Some With Advanced Cutaneous T Cell Lymphomas

the ONA take:

Allogeneic stem cell transplantation may result in long-term remissions in a subset of patients with advanced cutaneous T cell lymphomas (CTCL), a new study published online ahead of print in the journal Annals of Oncology has shown.

Because patients with advanced CTCL and large cell transformation are incurable with standard treatments, researchers from The University of Texas MD Anderson Cancer Center in Houston sought to evaluate the outcomes of patients with advanced CTCL undergoing allogeneic stem cell transplantation.

In the prospective case series, researchers report the outcomes of 47 patients with CTCL who underwent allogeneic stem cell transplantation after failure of standard therapy.

Results showed that 4-year overall survival was 51% and 4-year progression-free survival was 26%. Researchers found that 4-year progression-free survival was superior in patients who had leukemic Sézary Syndrome, a common variant of CTCL, compared with those who did not.

In regard to safety, the cumulative incidences of grades 2 to 4 acute graft-versus-host disease (GVHD) and chronic GVHD were 40% and 28%, respectively.